We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Novel Diagnostic Technology Rapidly Identifies Cancer Source

By LabMedica International staff writers
Posted on 28 Oct 2015
Print article
Image: The HiSeq 2500 ultra-high-throughput sequencing system (Photo courtesy of Illumina).
Image: The HiSeq 2500 ultra-high-throughput sequencing system (Photo courtesy of Illumina).
A substantial proportion of cancer cases present with a metastatic tumor and require further testing to determine the primary site; many of these are never fully diagnosed and remain cancer of unknown primary origin (CUP).

A diagnostic method for determining the primary site of the cancer combines genetics and computer science, and can analyze a biopsy from a metastasis, and on this basis provide a number of possible scenarios for where the cancer may have developed and indicate the probability of it being correct.

Scientists at the Technical University of Denmark (Lyngby, Denmark) in collaboration with their international colleagues, used the Catalogue of Somatic Mutations in Cancer (COSMIC) version 68 Whole Genomes database to identify tumor specimens with genome-wide or exome-wide somatic point mutation data, and focused on solid non-central nervous system (CNS) tumors of the ten primary sites for which at least 200 unique specimens were available. The newly developed method, which the team is calling TumorTracer, is based on analyses of DNA mutations in cancer tissue samples from patients with metastasized cancer.

The data set consisted of 7,769 specimens from 28 different primary sites. Some samples were paired-end multiplex sequenced on the HiSeq 2500 (Illumina, San Diego, CA, USA). The pattern of mutations was analyzed in a computer program which had been trained to find possible primary tumor localizations. The method has been tested on many thousands of samples where the primary tumor was already identified, and it has proven extremely precise. The next step will be to test the method on patients with unknown primary tumors. In recent years, scientists have discovered several ways of using genome sequencing of tumors to predict whether an individual cancer patient will benefit from a specific type of medicine.

Aron Charles Eklund, PhD, a professor and senior author of study, said, “We are very pleased that we can now use the same sequencing data together with our new algorithms to provide a much faster diagnosis for cancer cases that are difficult to diagnose, and to provide a useful diagnosis in cases which are currently impossible to diagnose. At the moment, it takes scientist two days to obtain a biopsy result, but we expect this time to be reduced as it becomes possible to do the sequencing increasingly faster, and it will be straightforward to integrate the method with the methods already being used by doctors.” The study was published on October 1, 2015, in the journal BMC Medical Genomics.

Related Links:

Technical University of Denmark


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.